SYNCOM FORMULATIONS (INDIA)
|
SYNCOM FORMULATIONS (INDIA) Last 5 Year Financial Ratios History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 0.81 | 0.53 | 0.27 | 0.21 | 0.23 |
| CEPS(Rs) | 0.88 | 0.58 | 0.32 | 0.26 | 0.28 |
| DPS(Rs) | 0.10 | - | - | - | 0.03 |
| Book NAV/Share(Rs) | 4.41 | 3.64 | 3.07 | 2.72 | 2.52 |
| Tax Rate(%) | 24.41 | 24.54 | 25.44 | 24.47 | 24.39 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 15.83 | 11.64 | 11.26 | 8.87 | 9.12 |
| EBIT Margin(%) | 20.91 | 14.27 | 14.59 | 13.37 | 12.79 |
| Pre Tax Margin(%) | 20.67 | 14.09 | 12.89 | 11.85 | 11.92 |
| PAT Margin (%) | 15.63 | 10.63 | 9.61 | 8.95 | 9.01 |
| Cash Profit Margin (%) | 16.96 | 11.75 | 11.40 | 10.97 | 10.81 |
| Performance Ratios | |||||
| ROA(%) | 16.06 | 12.02 | 6.45 | 5.85 | 8.04 |
| ROE(%) | 20.19 | 15.69 | 9.30 | 8.48 | 11.83 |
| ROCE(%) | 26.80 | 18.77 | 10.98 | 9.68 | 13.72 |
| Asset Turnover(x) | 1.03 | 1.13 | 0.67 | 0.65 | 0.89 |
| Sales/Fixed Asset(x) | 3.23 | 3.31 | 2.22 | 2.21 | 2.28 |
| Working Capital/Sales(x) | 2.16 | 2.21 | 1.57 | 3.27 | 3.57 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.31 | 0.30 | 0.45 | 0.45 | 0.44 |
| Receivable days | 81.35 | 82.75 | 123.89 | 116.42 | 94.33 |
| Inventory Days | 38.88 | 24.49 | 29.30 | 33.13 | 24.52 |
| Payable days | 91.02 | 46.59 | 69.17 | 62.08 | 79.52 |
| Valuation Parameters | |||||
| PER(x) | 12.67 | 31.28 | 41.52 | 27.63 | 46.32 |
| PCE(x) | 11.67 | 28.31 | 34.99 | 22.54 | 38.62 |
| Price/Book(x) | 2.33 | 4.52 | 3.65 | 2.17 | 4.22 |
| Yield(%) | 0.97 | - | - | - | 0.28 |
| EV/Net Sales(x) | 1.97 | 3.33 | 4.01 | 2.81 | 4.43 |
| EV/Core EBITDA(x) | 8.86 | 21.66 | 24.45 | 18.24 | 30.42 |
| EV/EBIT(x) | 9.42 | 23.35 | 27.47 | 20.99 | 34.66 |
| EV/CE(x) | 2.31 | 4.47 | 2.93 | 1.85 | 3.48 |
| M Cap / Sales | 1.98 | 3.33 | 3.99 | 2.47 | 4.17 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 5.20 | 76.55 | 17.45 | 2.09 | 18.85 |
| Core EBITDA Growth(%) | 51.99 | 65.76 | 25.14 | 7.72 | 65.57 |
| EBIT Growth(%) | 54.08 | 72.74 | 28.20 | 6.66 | 73.35 |
| PAT Growth(%) | 54.62 | 95.28 | 26.13 | 1.42 | 87.87 |
| EPS Growth(%) | 54.63 | 95.28 | 26.14 | -6.97 | 70.10 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | - | 0.01 | 0.25 | 0.32 | 0.27 |
| Current Ratio(x) | 3.13 | 4.42 | 2.55 | 1.61 | 1.79 |
| Quick Ratio(x) | 2.54 | 3.75 | 2.35 | 1.42 | 1.54 |
| Interest Cover(x) | 88.55 | 76.75 | 8.59 | 8.81 | 14.58 |
| Total Debt/Mcap(x) | - | - | 0.07 | 0.15 | 0.06 |
Compare Financial Ratios of peers of SYNCOM FORMULATIONS (INDIA)
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| SYNCOM FORMULATIONS (INDIA) | ₹1,885.6 Cr | 1.3% | 17.8% | 12.2% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹444,717.0 Cr | -0.8% | -2.5% | 11.9% | Stock Analytics | |
| DIVIS LABORATORIES | ₹255,115.0 Cr | 1.9% | 6.6% | 55.1% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹189,613.0 Cr | 0.3% | 2% | 35.9% | Stock Analytics | |
| CIPLA | ₹112,876.0 Cr | 0.9% | -0.8% | -10.9% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹100,395.0 Cr | 0.1% | 1.4% | -9.3% | Stock Analytics | |
SYNCOM FORMULATIONS (INDIA) Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| SYNCOM FORMULATIONS (INDIA) | 1.3% |
17.8% |
12.2% |
| SENSEX | -0.5% |
-4.8% |
-11% |
You may also like the below Video Courses
